Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases
Journal of Medicinal Chemistry · 08.05.2025 · 68 (9) · 9279-9302
DOI: 10.1021/acs.jmedchem.4c02883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.04.2025. Verfasst von Kairui Yue und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266071, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Histone Deacetylase 6, Inflammasomes, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China, Taishan Scholar Project of Shandong Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Previously, we found that hydrazide can serve as zinc binding groups for selective HDAC6 inhibitors and identified the first hydrazide-based HDAC6 inhibitor, 35m, which exhibited modest isoform selectivity. This study aimed to improve the HDAC6 selectivity of 35m, thereby reducing its side effects. Extensive structure-activity relationship studies revealed that the introduction of fluorine atoms at the 2 and 5 positions of the linker phenyl ring in compound 35m significantly enhanced its HDAC6 selectivity while maintaining its potency. The representative compound 9m demonstrated an IC50 of 0.021 μM against HDAC6, exhibiting at least 335-fold selectivity over other isoforms, along with favorable pharmacokinetic properties and improved safety profiles. Compound 9m inhibits the activation of NLRP3 inflammasome and significantly alleviates symptoms in multiple NLRP3 inflammasome-related disease models, including acute peritoneal, inflammatory bowel disease, and psoriasis. This study enriches the design strategies for selective HDAC6 inhibitors and provides a lead compound for NLRP3 inflammasome-related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266071, China.
- Department of Cardiology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei 230001, China.
- Marine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
ORCID-Profile: Yuqi Jiang, Xiaoyang Li
Förderung
- Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
- Taishan Scholar Project of Shandong Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Science Foundation for Excellent Young Scholars of Shandong Province
Zitieren
APA
Yue, K., Sun, S., Yin, Z., Liu, E., Jia, G., Jiang, Y., Duan, Y., Chen, Y., & Li, X. (2025). Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases. Journal of Medicinal Chemistry, 68(9), 9279-9302. https://doi.org/10.1021/acs.jmedchem.4c02883
Vancouver
Yue K, Sun S, Yin Z, Liu E, Jia G, Jiang Y, et al. Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases. Journal of Medicinal Chemistry. 2025;68(9):9279-9302. doi:10.1021/acs.jmedchem.4c02883
BibTeX
@article{Yue2025,
author = {Yue, Kairui and Sun, Simin and Yin, Zequn and Liu, Enqiang and Jia, Geng and Jiang, Yuqi and Duan, Yajun and Chen, Yuxin and Li, Xiaoyang},
title = {Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {9},
pages = {9279--9302},
doi = {10.1021/acs.jmedchem.4c02883}
}
EUVIMED